Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Sulodexide

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Sulodexide?

Sulodexide is an investigational drug.

There have been 14 clinical trials for Sulodexide. The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2011.

The most common disease conditions in clinical trials are Kidney Diseases, Diabetic Nephropathies, and Albuminuria. The leading clinical trial sponsors are Keryx Biopharmaceuticals, Collaborative Study Group (CSG), and Alfa Wassermann S.p.A.

There are ninety-two US patents protecting this investigational drug and four hundred and thirty-five international patents.

Recent Clinical Trials for Sulodexide
Management of Endothelial Dysfunction in Patients With Chronic Venous Insufficiency After Endovenous Surgical ProcedureState Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of RussiaN/A
Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)University Medical Center GroningenPhase 4
Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)Steno Diabetes CenterPhase 4

See all Sulodexide clinical trials

Clinical Trial Summary for Sulodexide

Top disease conditions for Sulodexide
Top clinical trial sponsors for Sulodexide

See all Sulodexide clinical trials

US Patents for Sulodexide

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Sulodexide   Start Trial Methods, kits and devices for promoting cardiac regeneration Yeda Research and Development Co. Ltd. (Rehovot, IL) Victor Chang Cardiac Research Institute (Darlinghurst, AU)   Start Trial
Sulodexide   Start Trial Nucleic acid vaccines ModernaTX, Inc. (Cambridge, MA)   Start Trial
Sulodexide   Start Trial Polynucleotides encoding immune modulating polypeptides ModernaTX, Inc. (Cambridge, MA)   Start Trial
Sulodexide   Start Trial Combination PIV3/hMPV RNA vaccines ModernaTX, Inc. (Cambridge, MA)   Start Trial
Sulodexide   Start Trial Human cytomegalovirus RNA vaccines ModernaTX, Inc. (Cambridge, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Sulodexide

Drugname Country Document Number Estimated Expiration Related US Patent
Sulodexide Australia 2015249553 2034-04-23   Start Trial
Sulodexide Brazil 112016024644 2034-04-23   Start Trial
Sulodexide Canada 2946751 2034-04-23   Start Trial
Sulodexide China 106659803 2034-04-23   Start Trial
Sulodexide European Patent Office 3134131 2034-04-23   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.